
Moderna Tops Revenue Estimates at $1.3 Billion as Net Income Turns Positive
The company raised its 2026 revenue growth outlook to 15% to 25% and expects year-end cash and investments of $8.1 billion to $8.3 billion.
Moderna, Inc. · Nasdaq · Biological Products, (No Diagnostic Substances)

The company raised its 2026 revenue growth outlook to 15% to 25% and expects year-end cash and investments of $8.1 billion to $8.3 billion.
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 15, 2026 | Stephen Hoge President | Sold 10b5-1 plan | 39,145 | $220.72 | $8.64 million |
| Oct. 14, 2026 | Stephen Hoge President | Sold 10b5-1 plan | 39,224 | $213.48 $213.47-$214.15 | $8.37 million |
| Sept. 15, 2026 | Stephen Hoge President | Sold 10b5-1 plan | 40,281 | $146.07 | $5.88 million |
| Sept. 14, 2026 | Stephen Hoge President | Sold 10b5-1 plan | 40,294 | $144.13 | $5.81 million |
| Sept. 10, 2026 | James M. Mock Chief Financial Officer | Sold 10b5-1 plan | 34,836 | $134.49 | $4.69 million |
| Sept. 1, 2026 | Shannon Thyme Klinger Chief Legal Officer | Sold 10b5-1 plan | 3,471 | $139.95 | $485,766 |
| Aug. 5, 2026 | Stephane Bancel Chief Executive Officer, director | Sold 10b5-1 plan | 499,246 | $57.52 $56.21-$58.79 | $28.72 million |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedModerna Q3 2026 GAAP EPS of $0.38 beats -$1.25 consensus on $1.3 billion revenue; raises 2026 revenue growth outlook to 15%-25%
Departure/appointment of directors or officers · Regulation FD disclosure · Financial statements and exhibits